{"name":"Mario Castro, MD, MPH","slug":"mario-castro-md-mph","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hyperpolarized Xe129","genericName":"Hyperpolarized Xe129","slug":"hyperpolarized-xe129","indication":"Diagnosis and monitoring of cancer","status":"phase_2"}]}],"pipeline":[{"name":"Hyperpolarized Xe129","genericName":"Hyperpolarized Xe129","slug":"hyperpolarized-xe129","phase":"phase_2","mechanism":"Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions.","indications":["Diagnosis and monitoring of cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE93dzhtU2E0TThWQ2Y3dnFDNE1IS09zWUgtVEI2d0pNLWRZZ1FXcGNiSEtjbWNKbWc4eHpoN1NWQWdvVmQyOU9fSDBnck9KdmJMMEVFeE96RHoyN0o3cy1JemhxajVPZw?oc=5","date":"2025-05-20","type":"pipeline","source":"MedPage Today","summary":"Tezepelumab Cuts Oral Corticosteroid Use in Severe Asthma - MedPage Today","headline":"Tezepelumab Cuts Oral Corticosteroid Use in Severe Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcWVaQkEtRTBBOWVFRDJOdXdJSnhFSEE3eTIzcFh0MV9pakhiVnZyM1gzMlhsNWJtaWJmbWNlTmlfSEE1ZW5nR3lXb2ttWVQyZzhoNkM0THB1ckFfRnhQNzcxSjVVZ3E4OHQ2LTE5UkFCRnNsRkVTaHJzVjZkemY1M0NJTjZvTnQ4TlBrM0JxZG9vdGVfbkNBOUZaM2J6cm9qcmI1N2IxUnd3dXVDdXFkd0wtQVZLWllQcmJKeExoZ3BCZjQ?oc=5","date":"2024-05-29","type":"pipeline","source":"Healio","summary":"Dupilumab associated with significant reductions in mucus plugging, volume - Healio","headline":"Dupilumab associated with significant reductions in mucus plugging, volume","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1LTFJtTmNYZDNFTjI2azIwVjQ2T08ycERNazI2ekNBa0dsUUR3Y3RQMlpDN0xNN2NDdjVQUjZ6Y3g1MVVUNDVWU1R5RVlTWEc3amZwNU9vNS0ybXRXUl9Udw?oc=5","date":"2018-05-21","type":"pipeline","source":"NEJM","summary":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma - NEJM","headline":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBkcGUyUTZBTmJlb3diNXprZ0VrYnplbDNUOFlVa2wyRVZkajRhSzlRWHR1bzRfbzBwdzVMNWZRNExKMUZ1UzhUMTlSQTFoUndkY0U5dEQ3Q00ydE14b0Rz?oc=5","date":"2018-05-21","type":"pipeline","source":"NEJM","summary":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma - NEJM","headline":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBQTU5hSGQzelpudkZjT2daRjc5d21LUUt6YWJPVklXUVlDclh3M1VyVWNibzg2OFZiMU8wOE1OYnRLNTI4T1FxX09jd3RyZkJUalNXTjA0am9uekJIZmxNbg?oc=5","date":"2018-05-21","type":"pipeline","source":"NEJM","summary":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma - NEJM","headline":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPcFJkdC14REVlNGlNbWpINkJ0YXNJRzZNOUM5RkY1UUlWX054QnVxNXFCOFg2UllaSnFUVzNrMkxVVUpRLVJVbDhMTk5xaEFxb3dDakQ3SWJnQUw2aGVfTVJycUQ2M3hyYTZWZmNxdXgwaU9VYnRBdVpyRmdCSTd1dUF2aWdVT3pOejkzTFNkQW9BSXJxdlo5SE1mOFNBdUNRTEtId1FUdVJzZVZZdEtkQ1lva1d6eWpjalJaNWJ3?oc=5","date":"2016-03-24","type":"regulatory","source":"Pharmacy Practice News","summary":"FDA Approves Cinqair To Treat Severe Asthma - Pharmacy Practice News","headline":"FDA Approves Cinqair To Treat Severe Asthma","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}